YYYöntem Yaman

Yöntem Yaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yöntem Yaman has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world outcomes of children with first relapsed acute lymphoblastic leukemia treated according to the ALL-IC REL 2016 guideline in Türkiye

    by Volkan Hazar, Adalet Meral Güneş, Hüsniye Neşe Yaralı, Koray Yalçın, Funda Tayfun Küpesiz, Tuba Hilkay Karapınar, Ali Ayçiçek, Emine Zengin, Melike Sezgin Evim, Namık Yaşar Özbek, et al.

  • Open Access

    Pazopanib as maintenance therapy in pediatric ewing sarcoma: a case series of six patients

    by Nihan Bayram, Murat Elli, Yontem Yaman, Isık Odaman Al, Kursat Ozdilli, Dilek Unal, Harzem Ozger, Sema Anak

    Introduction: Ewing sarcoma (ES) is an aggressive pediatric bone and soft tissue malignancy. Despite advances in multimodal therapy, outcomes remain suboptimal for patients with high-risk features such as large tumor volume, poor histologic response, disseminated disease, or relapse. Maintenance strategies have gained interest in pediatric sarcomas, but evidence in ES is limited. Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, has shown activity in adult soft tissue sarcomas; however, data on its use as maintenance therapy in pediatric ES are scarce. Methods: We retrospectively analyzed six pediatric ES patients who received pazopanib as maintenance therapy following consolidation treatment or, when applicable, after high-dose chemotherapy with autologous stem cell transplantation. Indications included poor-risk localized disease, relapse, or stable residual disease after frontline therapy. Pazopanib dosing, duration, toxicity, and clinical outcomes were reviewed. Results: Pazopanib was administered at doses of 400–800 mg in five patients and 200 mg twice daily in one patient. Hair depigmentation occurred in all patients, and one patient developed reversible hepatotoxicity requiring temporary interruption and dose reduction. At a median follow-up of 47 months (range, 18–53 months), five patients remained in complete remission. One patient with disseminated disease at diagnosis developed intracranial relapse 18 months post-transplant while still receiving pazopanib. Conclusions: In this retrospective cohort, pazopanib was generally well tolerated and may have a potential role as maintenance therapy in selected high-risk pediatric ES patients. However, efficacy cannot be determined from this limited series, and prospective studies are needed to better define its clinical utility in ES.

  • Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center Experience

    by Nihan Bayram, Yontem Yaman, Kursat Ozdilli, Serdar Nepesov, Isik Odaman Al, Murat Elli, Sema Anak

    Introduction: Thrombocytopenia is a common clinical problem in cancer patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). It can occur as prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) and may cause potentially fatal bleeding. However, data on the treatment of post-transplant thrombocytopenia is still lacking. Methods: We reported our practices involving 15 pediatric patients who received eltrombopag (ELT) treatment for PIT and SFPR after autologous HSCT. Results: The overall response was 78.5% (11/14), with 1 patient excluded due to noncompliance. The 12 surviving patients' median follow up was 699 days (range: 167 to 2250 d). Conclusions: Our study indicates the efficacy and safety of ELT for treating PIT and SFPR after autologous HSCT in pediatric patients. However, more studies are needed to confirm these findings in children.


  • Open Access

    Clinical, Genetic, and Outcome Characteristics of Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

    by Serdar Nepesov, Yöntem Yaman, Murat Elli, Nihan Bayram, Kürşat Özdilli, Ayça Kıykım, Deniz Çakır, Betül Kılıç, Kürşad Aydın, Akif Ayaz, et al.

    Objective: In this study, we sought to describe the clinical, laboratory, and genetic character- istics of patients diagnosed with primary hemophagocytic lymphohistiocytosis. Thus, we aimed to evaluate the early diagnosis and appropriate treatment options for pediatric hemophago- cytic lymphohistiocytosis patients. Materials and Methods: Medical records of 9 patients diagnosed with primary hemophago- cytic lymphohistiocytosis between November 2013 and December 2019 were analyzed retro- spectively. Clinical, genetic, and laboratory characteristics, family histories, initial complaints, physical examination findings, age at diagnosis, treatment choices, and clinical follow-up of all patients were investigated. Results: The mean age at diagnosis was 11 months (range: 1.5 months to 17 years). Genetic analysis was performed in all patients, and a disease-related mutation was detected in 8 (89%) of them. Among clinical features, 6 (66%) patients had fever, 5 (56%) had splenomegaly, 4 (44%) had lymphadenopathy, 4 (44%) had skin rash, and 4 (44%) had neurological findings. Hemophagocytosis was observed in the bone marrow samples of 6 (66%) patients. Disease remission was achieved in 7 (78%) patients. Hematopoietic stem cell transplantation was per- formed in 7 (78%) patients. Conclusion: Hemophagocytic lymphohistiocytosis may present with different clinical symptoms that can cause a significant diagnostic delay. The only curative treatment option in primary hemophagocytic lymphohistiocytosis patients is hematopoietic stem cell transplantation. The chemotherapy should be started as early as possible, in order to achieve a disease remission. Patients should be referred to the appropriate bone marrow transplant center for hematopoi- etic stem cell transplantation as soon as they reach the disease remission. Cite this article as: Nepesov S, Yaman Y, Elli M, et al. Clinical, genetic, and outcome characteristics of pediatric patients with primary hemophagocytic lymphohistiocytosis. Turk Arch Pediatr. 2022;57(4):398-405.


  • HLA ‐ matched related donor hematopoietic stem cell transplantation in a patient with polynucleotide kinase 3–phosphatase mutation developed acute myeloid leukemia

    by Nihan Bayram, Yontem Yaman, Murat Elli, Kursat Ozdilli, Serdar Nepesov, Mehmet Sait Dogan, Akif Ayaz, Sema Anak

    Background: PNPK gene mutations result in DNA repair disorders and have a spectrum of neurodevelopmental manifestations. To date, cancer predisposition has not been described in patients with PNKP mutations.Observation: Here, we report a patient with PNKP mutation, who developed AML at age of five and underwent reduced‐intensity HSCT.Conclusion: Although many DNA repair disorders are known to have increased risk of malignancy, association between PNKP mutations and malignancy is not well‐described. This report is the first description of a PNPK mutation patient developing a malignancy and undergoing curative HSCT.


  • Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia

    by Nihan Bayram, Yöntem Yaman, Kürşat Özdilli, Leyla Telhan, Serdar Nepesov, Hülya Bilgen, Murat Elli, Sude Sema Behar, Sema Anak

    Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.


  • Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience

    by Yöntem Yaman, Murat Elli, Şifa Şahin, Kürşat Özdilli, Hülya Bilgen, Nihan Bayram, Serdar Nepesov, Sema Anak

    Delayed recovery of thrombocytopenia is a well‐known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post‐allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/µL. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/µL and 50 000/µL was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm3. In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.


  • Effects of Genetic Modifiers on Clinics of Beta Thalassemia Major and Intermedia

    by Yöntem Yaman, Özgür Cartı, Gulcihan Özek, Huseyin Onay, Berna Atabay, Canan Vergin

  • Open Access

    Non-typhoidal Salmonella bacteraemia in paediatric leukaemia patients

    by Yöntem Yaman, İlKer Devrim, Gulcihan Ozek, Bengü Demirağ, Yeşim Oymak, Gamze Gülfidan, Canan Vergin

    Non-typhoidal Salmonella (NTS) is an important pathogen that causes gastroenteritis, bacteraemia, and focal infections. Herein, we present our experience with bloodstream infections caused by Salmonella in paediatric leukaemia patients, which has been reported for the first time in both Europe...


  • Open Access

    Secondary hemophagocytic lymphohistiocytosis in children with brucellosis: report of three cases

    by Yöntem Yaman, Salih Gözmen, Ahmet Kağan Özkaya, Yeşim Oymak, Hurşit Apa, Canan Vergin, İlKer Devrim

    Brucellosis is a systemic zoonotic infectious disease that may cause fever, fatigue, sweating, arthritis, hepatosplenomegaly, cytopenia, and lymphadenopathy. It continues to be an important health problem worldwide. Hemophagocytic lymphohistiocytosis (HLH) is characterized by fever, hepatosplenomegaly, cytopenias, high serum levels of ferritin and triglycerides, low serum fibrinogen levels, and hemophagocytosis in bone marrow, lymph nodes, spleen, or liver. Hemophagocytic lymphohistiocytosis associated with brucellosis is a very rare condition in the pediatric age group. Here, three pediatric cases of secondary HLH associated with brucellosis are reported. Hemophagocytic lymphohistiocytosis should be considered in patients with brucellosis having cytopenias. Hemophagocytosis in brucellosis seems to be cured with appropriate antibiotics and intravenous immunoglobulin.